aerosolized glutathione The Treatment of Pulmonary Diseases and Respiratory-Related Conditions with Inhaled (Nebulized or Aerosolized) Nebulizer Glutathione - Lungs &

The compound has been the subject of extensive preclinical research, particularly in models studying tissue repair, angiogenesis, and gastrointestinal mucosal integrity

Assign CPT code 70472 to SI of `N' (Items and Services Packaged into APC Rates

Substances 0.000 description 3 230000001681 protective effect Effects 0.000 description 3 231100000161 signs of toxicity Toxicity 0.000 description 3 239000000741 silica gel Substances 0.000 description 3 229910002027 silica gel Inorganic materials 0.000 description 3 238000002560 therapeutic procedure Methods 0.000 description 3 229940036248 turpentine Drugs 0.000 description 3 206010001541 Akinesia Diseases 0.000 description 2 IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2 QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2 CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2 239000004472 Lysine Substances 0.000 description 2 YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2 NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2 239000004793 Polystyrene Substances 0.000 description 2 208000004006 Tick-borne encephalitis Diseases 0.000 description 2 RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2 KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2 230000007059 acute toxicity Effects 0.000 description 2 231100000403 acute toxicity Toxicity 0.000 description 2 125000003277 amino group Chemical group 0.000 description 2 235000003704 aspartic acid Nutrition 0.000 description 2 OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2 230000036772 blood pressure Effects 0.000 description 2 TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2 239000003153 chemical reaction reagent Substances 0.000 description 2 238000003776 cleavage reaction Methods 0.000 description 2 230000005595 deprotonation Effects 0.000 description 2 238000010537 deprotonation reaction Methods 0.000 description 2 238000011161 development Methods 0.000 description 2 238000010790 dilution Methods 0.000 description 2 239000012895 dilution Substances 0.000 description 2 230000003292 diminished effect Effects 0.000 description 2 MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2 231100000673 doseresponse relationship Toxicity 0.000 description 2 239000003814 drug Substances 0.000 description 2 239000003937 drug carrier Substances 0.000 description 2 238000001704 evaporation Methods 0.000 description 2 230000008020 evaporation Effects 0.000 description 2 210000003754 fetus Anatomy 0.000 description 2 235000013922 glutamic acid Nutrition 0.000 description 2 230000002008 hemorrhagic effect Effects 0.000 description 2 239000001257 hydrogen Substances 0.000 description 2 229910052739 hydrogen Inorganic materials 0.000 description 2 231100000252 nontoxic Toxicity 0.000 description 2 230000003000 nontoxic effect Effects 0.000 description 2 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2 229910052763 palladium Inorganic materials 0.000 description 2 229920002223 polystyrene Polymers 0.000 description 2 230000035935 pregnancy Effects 0.000 description 2 125000006239 protecting group Chemical group 0.000 description 2 230000007017 scission Effects 0.000 description 2 210000004894 snout Anatomy 0.000 description 2 125000001424 substituent group Chemical group 0.000 description 2 238000006467 substitution reaction Methods 0.000 description 2 230000002459 sustained effect Effects 0.000 description 2 230000008961 swelling Effects 0.000 description 2 238000012360 testing method Methods 0.000 description 2 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2 ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1 OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1 OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1 OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1 206010002091 Anaesthesia Diseases 0.000 description 1 208000031295 Animal disease Diseases 0.000 description 1 CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1 OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1 208000001490 Dengue Diseases 0.000 description 1 206010012310 Dengue fever Diseases 0.000 description 1 206010053172 Fatal outcomes Diseases 0.000 description 1 DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1 239000004471 Glycine Substances 0.000 description 1 208000032843 Hemorrhage Diseases 0.000 description 1 208000006083 Hypokinesia Diseases 0.000 description 1 XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1 241000699666 Mus Species 0.000 description 1 101710176384 Peptide 1 Proteins 0.000 description 1 241000700157 Rattus norvegicus Species 0.000 description 1 108010081750 Reticulin Proteins 0.000 description 1 238000012300 Sequence Analysis Methods 0.000 description 1 206010072170 Skin wound Diseases 0.000 description 1 208000007107 Stomach Ulcer Diseases 0.000 description 1 208000025865 Ulcer Diseases 0.000 description 1 238000010521 absorption reaction Methods 0.000 description 1 239000000654 additive Substances 0.000 description 1 230000000996 additive effect Effects 0.000 description 1 125000005907 alkyl ester group Chemical group 0.000 description 1 125000000746 allylic group Chemical group 0.000 description 1 150000001408 amides Chemical class 0.000 description 1 238000001949 anaesthesia Methods 0.000 description 1 230000037005 anaesthesia Effects 0.000 description 1 238000004458 analytical method Methods 0.000 description 1 230000001430 anti-depressive effect Effects 0.000 description 1 230000003501 anti-edematous effect Effects 0.000 description 1 239000000935 antidepressant agent Substances 0.000 description 1 229940005513 antidepressants Drugs 0.000 description 1 230000009876 antimalignant effect Effects 0.000 description 1 QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1 150000001540 azides Chemical class 0.000 description 1 230000008901 benefit Effects 0.000 description 1 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1 230000000740 bleeding effect Effects 0.000 description 1 230000037396 body weight Effects 0.000 description 1 210000000988 bone and bone Anatomy 0.000 description 1 239000007853 buffer solution Substances 0.000 description 1 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1 210000004899 c-terminal region Anatomy 0.000 description 1 239000002775 capsule Substances 0.000 description 1 238000006243 chemical reaction Methods 0.000 description 1 230000027326 copulation Effects 0.000 description 1 239000012043 crude product Substances 0.000 description 1 125000004122 cyclic group Chemical group 0.000 description 1 UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1 229940097265 cysteamine hydrochloride Drugs 0.000 description 1 230000003247 decreasing effect Effects 0.000 description 1 208000025729 dengue disease Diseases 0.000 description 1 238000001514 detection method Methods 0.000 description 1 230000008034 disappearance Effects 0.000 description 1 230000003291 dopaminomimetic effect Effects 0.000 description 1 229940079593 drug Drugs 0.000 description 1 230000000373 effect on fracture Effects 0.000 description 1 238000010828 elution Methods 0.000 description 1 125000004185 ester group Chemical group 0.000 description 1 230000012173 estrus Effects 0.000 description 1 230000002349 favourable effect Effects 0.000 description 1 239000000945 filler Substances 0.000 description 1 238000001914 filtration Methods 0.000 description 1 201000005917 gastric ulcer Diseases 0.000 description 1 239000000499 gel Substances 0.000 description 1 239000004220 glutamic acid Substances 0.000 description 1 230000002443 hepatoprotective effect Effects 0.000 description 1 NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1 OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1 230000003483 hypokinetic effect Effects 0.000 description 1 230000001771 impaired effect Effects 0.000 description 1 238000000338 in vitro Methods 0.000 description 1 238000001727 in vivo Methods 0.000 description 1 208000015181 infectious disease Diseases 0.000 description 1 230000036512 infertility Effects 0.000 description 1 208000000509 infertility Diseases 0.000 description 1 231100000535 infertility Toxicity 0.000 description 1 210000004969 inflammatory cell Anatomy 0.000 description 1 238000002329 infrared spectrum Methods 0.000 description 1 229940102223 injectable solution Drugs 0.000 description 1 238000011081 inoculation Methods 0.000 description 1 239000002054 inoculum Substances 0.000 description 1 OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1 230000003902 lesion Effects 0.000 description 1 231100000518 lethal Toxicity 0.000 description 1 230000001665 lethal effect Effects 0.000 description 1 239000006210 lotion Substances 0.000 description 1 239000011159 matrix material Substances 0.000 description 1 230000001404 mediated effect Effects 0.000 description 1 229960003151 mercaptamine Drugs 0.000 description 1 XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1 230000004899 motility Effects 0.000 description 1 230000010352 nasal breathing Effects 0.000 description 1 210000002850 nasal mucosa Anatomy 0.000 description 1 210000005036 nerve Anatomy 0.000 description 1 229910052757 nitrogen Inorganic materials 0.000 description 1 230000001473 noxious effect Effects 0.000 description 1 239000002674 ointment Substances 0.000 description 1 239000001301 oxygen Substances 0.000 description 1 229910052760 oxygen Inorganic materials 0.000 description 1 239000012071 phase Substances 0.000 description 1 239000002504 physiological saline solution Substances 0.000 description 1 230000002265 prevention Effects 0.000 description 1 239000000047 product Substances 0.000 description 1 238000000746 purification Methods 0.000 description 1 239000002516 radical scavenger Substances 0.000 description 1 230000009467 reduction Effects 0.000 description 1 JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1 238000004007 reversed phase HPLC Methods 0.000 description 1 238000007086 side reaction Methods 0.000 description 1 238000010532 solid phase synthesis reaction Methods 0.000 description 1 238000000935 solvent evaporation Methods 0.000 description 1 238000004611 spectroscopical analysis Methods 0.000 description 1 238000007619 statistical method Methods 0.000 description 1 230000004083 survival effect Effects 0.000 description 1 239000000725 suspension Substances 0.000 description 1 230000009182 swimming Effects 0.000 description 1 239000003826 tablet Substances 0.000 description 1 YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1 WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1 210000002303 tibia Anatomy 0.000 description 1 ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1 231100000397 ulcer Toxicity 0.000 description 1 238000002211 ultraviolet spectrum Methods 0.000 description 1 239000004474 valine Substances 0.000 description 1 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1 230000001018 virulence Effects 0.000 description 1 238000005406 washing Methods 0.000 description 1 Images Classifications CCHEMISTRY

Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. American Journal of Health-System Pharmacy , 2003